Barclays
IBRX icon

Barclays’s ImmunityBio IBRX Stock Holding History

Barclays’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.81M Buy
+510,000
New +$4.08M ﹤0.01% 2070
2026
Q2 		– Sell
-189,600
Closed -$1.45M – 5479
2026
Q1 		$1.45M Buy
+189,600
New +$1.3M ﹤0.01% 2534
2025
Q3 		– Sell
-120,000
Closed -$317K – 5599
2025
Q2 		$317K Buy
+120,000
New +$323K ﹤0.01% 4021
2024
Q2 		– Sell
-197,300
Closed -$1.06M – 5067
2024
Q1 		$1.06M Buy
+197,300
New +$893K ﹤0.01% 3074

Other funds holding IBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Clearwater Capital Advisors
Clearwater Capital Advisors Hoffman Estates, Illinois $1.39B AUM 12.56% 1-Year Est. Return

Barclays's IBRX Position: Q3 2026 in Review

Barclays reduced its ImmunityBio (IBRX) stake by 77% in Q3 2026, selling an estimated $4.49M and leaving 168,791 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

Barclays first reported a position in IBRX in Q4 2015 and has held it in 40 quarters since. The position peaked at $14.5M in Q1 2026. 231 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Barclays held 168,791 shares of ImmunityBio worth $1.59M as of Q3 2026.
  • Barclays sold 561,545 ImmunityBio shares in Q3 2026, an estimated $4.49M.
  • ImmunityBio made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2739 holding.
  • Barclays first reported a position in ImmunityBio in Q4 2015 and has held it in 40 quarters since.
  • Barclays's ImmunityBio position peaked at $14.5M in Q1 2026.
  • 231 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.